Endocrinology, Vol 137, 1585-1590, Copyright © 1996 by Endocrine Society

ARTICLES

Somatostatin antisense oligodeoxynucleotide-mediated stimulation of lymphocyte proliferation in culture

MC Aguila, AM Rodriguez, HN Aguila-Mansilla and WT Lee
Department of Physiology, University of Texas Southwestern Medical Center, Dallas 75235-8873, USA. Aguila@UTSW.SWMED.EDU

We have previously shown that somatostatin (SRIF) is synthesized in B and T lymphocytes of rat spleen and thymus and released into the medium of cultured lymphocytes. To determine the role of SRIF in the control of lymphocytes proliferation, the expression of SRIF in normal lymphocytes was inhibited using a 3'-terminal phosphorothioate-modified antisense oligonucleotide complementary to a sequence that includes the translation start site of the rat SRIF messenger RNA. Spleens were obtained from adult male rats, and their lymphocytes were cultured for 24 or 72 h to measure SRIF content and cell proliferation, respectively. For the proliferation studies, [3H]thymidine was incorporated during the final 18 h. The lymphocytes were incubated with 15-30 micrograms/ml SRIF antisense and control antisense. SRIF antisense (25 micrograms/ml) increased lymphocyte proliferation 15-fold (P < or = 0.001), reaching a plateau (25- to 30-fold increase) between 25-30 micrograms/ml SRIF antisense. SRIF was extracted from lymphocytes and measured by RIA. Levels of SRIF content were almost undetectable with 10 micrograms/ml antisense and were significantly lower (P < or = 0.01) with 25 micrograms/ml antisense. When RC 160 (10(-5) M), a SRIF agonist analog, was used in the incubation, the stimulation of cell proliferation exerted by the SRIF antisense was completely abolished. Control antisense had no effect on proliferation or SRIF content. These findings indicate that 1) lymphocytes in culture are able to incorporate SRIF antisense; and 2) SRIF antisense inhibits the expression of lymphocytic SRIF, which leads to lymphocyte proliferation. In conclusion, cell proliferation is dramatically increased by eliminating the expression of SRIF from the lymphocytes, which indicates that in vitro SRIF is acting in a paracrine and/or autocrine fashion to inhibit lymphocyte proliferation.

This article has been cited by other articles:

				V. A. S. H. Dalm, P. M. van Hagen, P. M. van Koetsveld, S. Achilefu, A. B. Houtsmuller, D. H. J. Pols, A.-J. van der Lely, S. W. J. Lamberts, and L. J. Hofland Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E344 - E353. [Abstract] [Full Text] [PDF]

				V. A. Dalm, P. M. van Hagen, P. M. van Koetsveld, A. W. Langerak, A.-J. van der Lely, S. W. Lamberts, and L. J. Hofland Cortistatin Rather Than Somatostatin as a Potential Endogenous Ligand for Somatostatin Receptors in the Human Immune System J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 270 - 276. [Abstract] [Full Text] [PDF]

				J. C. Reubi, J. A. Laissue, B. Waser, D. L. Steffen, R. W. Hipkin, and A. Schonbrunn Immunohistochemical Detection of Somatostatin sst2a Receptors in the Lymphatic, Smooth Muscular, and Peripheral Nervous Systems of the Human Gastrointestinal Tract: Facts and Artifacts J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2942 - 2950. [Abstract] [Full Text]

				S. KHARE, U. KUMAR, R. SASI, L. PUEBLA, L. CALDERON, K. LEMSTROM, P. HAYRY, and A. Y. C. PATEL Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty FASEB J, February 1, 1999; 13(2): 387 - 394. [Abstract] [Full Text]

				D. B. Reardon, P. Dent, S. L. Wood, T. Kong, and T. W. Sturgill Activation In Vitro of Somatostatin Receptor Subtypes 2, 3, or 4 Stimulates Protein Tyrosine Phosphatase Activity in Membranes from Transfected Ras-Transformed NIH 3T3 Cells: Coexpression with Catalytically Inactive SHP-2 Blocks Responsiveness Mol. Endocrinol., July 1, 1997; 11(8): 1062 - 1069. [Abstract] [Full Text]

				C. Benlot, L. Levy, P. Fontanaud, A. Roche, P. Rouannet, and D. Joubert Somatostatin and Growth Hormone-Releasing Hormone in Normal and Tumoral Human Breast Tissue: Endogenous Content, in Vitro Pulsatile Release, and Regulation J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 690 - 696. [Abstract] [Full Text] [PDF]